01 June 2024
: Case report
Simultaneous Acquisition of T790M Mutation and SCLC Transformation during Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma: A Rare Case Report
Unusual clinical course
Tatsuya Yazaki12AEF*, Masanobu Kimoto1E, Ayumi Minagawa1E, Takashi Maruno1E, Miwa Yamanaka12E, Kei Sonehara2EF, Mineyuki Hama1E, Toshitsugu Nakamura3E, Shintaro Kanda4E, Masayuki Hanaoka2E, Tsutomu Hachiya1EFDOI: 10.12659/AJCR.943466
Am J Case Rep 2024; 25:e943466
Table 2. Summary of treatments for each case.
Source | 1st line | 2nd line | 3rd line | 4th line | 5th line | 6th line | Duration of treatment after transformation |
---|---|---|---|---|---|---|---|
Tang K, et al []9 | Gefitinib | Over 14 months | |||||
Hirata Y, et al []10 | Afatinib | Carboplatin + Pemetrexed | Docetaxel | Over 8 months | |||
Current case | Erlotinib | Over 25 months | |||||
Bold type indicates a treatment after small cell lung carcinoma transformation. Case 1 was treated for over 14 months, Case 2 was treated for over 8 months, and Case 3 (our case) was treated for over 25 months after the transformation of EGFR-positive lung adenocarcinoma to SCLC. |